148741-64-4

Basic information

• Product Name: 2-(ISOPROPYLAMINO)PYRIMIDINE-5-CARBOXYLIC ACID
• Synonyms: 2-(ISOPROPYLAMINO)PYRIMIDINE-5-CARBOXYLIC ACID;2-(isopropylamino)pyrimidine-5-carboxylic acid(SALTDATA: FREE)
• CAS NO: 148741-64-4
• Molecular Formula: C8H11N3O2
• Molecular Weight: 181.19
• Mol File: 148741-64-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 371.1°C at 760 mmHg
• Flash Point: 178.2°C
• Appearance: /
• Density: 1.282g/cm³
• Vapor Pressure: 3.67E-06mmHg at 25°C
• Refractive Index: 1.598
• CAS DataBase Reference: 2-(ISOPROPYLAMINO)PYRIMIDINE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(ISOPROPYLAMINO)PYRIMIDINE-5-CARBOXYLIC ACID(148741-64-4)
• EPA Substance Registry System: 2-(ISOPROPYLAMINO)PYRIMIDINE-5-CARBOXYLIC ACID(148741-64-4)

Safety Data

• Hazardous Substances Data: 148741-64-4(Hazardous Substances Data)

Usage

Structure

Pyrimidine derivative with an isopropylamino group attached to the second carbon and a carboxylic acid group attached to the fifth carbon

Type

Chemical compound

Pharmaceutical applications

Potential use in the development of drugs for the treatment of various diseases

Importance in medicinal chemistry

Its chemical structure and properties make it a candidate for research and development in the field of medicinal chemistry.

InChI:InChI=1/C8H11N3O2/c1-5(2)11-8-9-3-6(4-10-8)7(12)13/h3-5H,1-2H3,(H,12,13)(H,9,10,11)

Upstream product

• 77476-95-0 (5-bromopyrimidin-2-yl)-N-isopropylamine 
• 148741-62-2 2-isopropylamino-5-methoxycarbonylpyrimidine 

Downstream Products

• 1581701-28-1 2-(isopropylamino)-N-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrimidine-5-carboxamide 

Relevant articles and documents

Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib

Epidermal growth factor receptor (EGFR) amplification has been demonstrated to be critical for the inherent and/or acquired resistance against current B-RafV600E inhibitor therapy for melanoma and colorectal cancer patients. We describe the discovery and structure-activity relationship study of a series of 1H-pyrazolo[3,4-b]pyridine-5-carboxamide analogues as novel dual inhibitors of EGFR and B-RafV600E mutant. One of the most promising compounds, 6a, potently inhibited both of the kinases with IC50 values of 8.0 and 51 nM, respectively. The compound also strongly suppressed the proliferation of a panel of intrinsic and acquired resistant melanoma and/or colorectal cancer cells harboring overexpressed EGFR with submicromolar IC 50 values. Further mechanism investigation revealed that 6a could sustainably inhibit the activation of the MAPK path way in the resistant SK-MEL-28 PR30 melanoma cancer cells and WiDr colorectal cancer cells with EGFR amplification. Our results support the hypothesis that the EGFR/B-Raf V600E dual inhibition might be a tractable strategy to overcome the intrinsic and acquired resistance of melanoma and/or colorectal cancers against the current B-RafV600E inhibitor therapy.